SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing significant volatility as investors weigh a surprise 75-million-share stock offering against better-than-expected revenue guidance and strong delivery numbers. The community is sharply divided, with some highlighting the necessity of raising capital to meet equity-matching requirements for a government loan and scale production, while others criticize the dilution as a recurring obstacle to long-term price appreciation.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is in the spotlight as investors debate the company's aggressive infrastructure spending and pivot toward monetizing excess AI compute capacity through potential cloud offerings. Community sentiment is deeply divided, with bulls pointing to the long-term value of Metas data center investments and potential AI model breakthroughs, while bears focus on capex concerns and increasing regulatory and legal pressures.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon Inc. (GRPN) is trending as investors discuss a potential structural short squeeze driven by a tight float, index inclusion, and active share buybacks. The community is highlighting a 'boxed' short position where the combination of institutional ownership and management's capital allocation leaves few shares available for shorts to cover, drawing frequent comparisons to past parabolic squeeze setups.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant community focus fueled by its high short interest, which traders are eyeing as a catalyst for a potential squeeze. Discussion is polarized between bullish participants highlighting the company's AI-focused partnerships and technical setup, and skeptics who remain wary of persistent price volatility and the lack of a clear, immediate move to the upside.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense community focus as traders debate the company's recent reverse stock split proposal, its aggressive Bitcoin accumulation strategy, and persistent volatility linked to its association with the Trump family. Investors are divided between those betting on significant upside potential driven by rising Bitcoin prices and legislative optimism, and others warning of ongoing dilution, management concerns, and structural risks.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently seeing significant investor focus following the appointment of Kathleen Tregoning, a veteran executive with a track record of guiding biotechs toward major acquisitions, to its board. The community is actively discussing the company's strong cash position, the upcoming Phase 3 durability data, and its potential as a first-mover in the treatment-resistant depression market as it advances toward an anticipated commercial launch.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors react to a combination of high short interest and speculative momentum, fueled by anticipation of commercial milestones in the drone, smart eyewear, and AI device sectors. Community discussion remains polarized, with bulls tracking manufacturing progress and potential partnerships while bears highlight ongoing execution risks and historical price volatility.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending following the FDAs accelerated approval of its IgA nephropathy treatment, Trutakna, which marks a significant commercial milestone for the company. Community discussion is focused on the drug's broad label, the potential for rapid commercial uptake, and the possibility of future M&A interest as investors weigh the stock's performance against the broader competitive landscape in the rare kidney disease sector.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as it navigates a major strategic shift toward an agentic AI-first operating model, recently headlined by a 20% workforce reduction that has sparked intense debate over the company's long-term profitability and AI monetization strategy. The community is actively dissecting the stock's volatile price action, weighing strong revenue growth and infrastructure dominance against concerns over premium valuation, margin pressure, and the operational impact of these significant staff cuts.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is currently the focus of significant market attention following a definitive $10 billion acquisition agreement by Vertex Pharmaceuticals at $85 per share in cash. Community members are actively debating the high premium, the strategic expansion into rare endocrine diseases, and the potential for rotation into other biotech merger candidates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion.
Tvardi Therapeutics (NASDAQ:TVRD)read more...

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock  

Equity

H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.

VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout 

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion.
Bluejay Diagnosticsread more...

Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more

These are the stocks posting the largest moves in early trading...

Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.read more...

SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing price on Monday.


Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, July 6, 2026...

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are celebrating a definitive $10 billion all-cash acquisition agreement that values the company at $85 per share.

With the share price trading tightly near the $85 cash offer, the stock has transitioned into a classic merger arbitrage play.

Traders are hunting for the next major takeover candidate in the biotech space following this massive acquisition premium.

Patience paid off for long-term shareholders as they enjoy a 100% gain following a period of persistent underperformance.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRNXCrinetics Pharmaceuticals Inc

Fundamentals

Latest CRNX News